GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » EBIT

LTR Pharma (ASX:LTP) EBIT : A$ Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma EBIT?

LTR Pharma's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2023 was A$-1.46 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LTR Pharma's annualized ROC % for the quarter that ended in Jun. 2023 was -439.14%. LTR Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -6,613.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

LTR Pharma EBIT Historical Data

The historical data trend for LTR Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma EBIT Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
EBIT
-0.03 -1.03 -1.46

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
EBIT -0.03 -1.03 -1.46

Competitive Comparison of LTR Pharma's EBIT

For the Biotechnology subindustry, LTR Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LTR Pharma's EV-to-EBIT falls into.


LTR Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was A$ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma  (ASX:LTP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LTR Pharma's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

ROC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-1.436 * ( 1 - 0% )/( (0.3 + 0.354)/ 2 )
=-1.436/0.327
=-439.14 %

where

Invested Capital(Q: Jun. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.245 - 0.466 - ( 1.911 - max(0, 0.476 - 1.955+1.911))
=0.3

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.51 - 0.011 - ( 7.145 - max(0, 0.021 - 7.21+7.145))
=0.354

Note: The Operating Income data used here is one times the annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

LTR Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2022  Q: Jun. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.455/( ( (0 + max(-0.432, 0)) + (0 + max(0.044, 0)) )/ 2 )
=-1.455/( ( 0 + 0.044 )/ 2 )
=-1.455/0.022
=-6,613.64 %

where Working Capital is:

Working Capital(Q: Jun. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.044) - (0.466 + 0 + 0.01)
=-0.432

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.065) - (0.011 + 0 + 0.01)
=0.044

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

LTR Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2023 )
=/84.563
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma EBIT Related Terms

Thank you for viewing the detailed overview of LTR Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » EBIT
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines